Cytek Biosciences reported a 6% increase in total revenue to $44.1 million for Q1 2026, driven by growth in service and reagent sales and an expanding installed base of instruments. However, the company faced higher operating expenses, particularly in general and administrative costs, leading to a net loss of $18.9 million, up from $11.4 million in Q1 2025. Cytek reaffirmed its 2026 revenue guidance of $205-$212 million, expecting continued growth amid global market challenges. The company highlights its technology leadership and recurring revenue expansion as key drivers for future performance.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
